Product Highlight - Alunbrig

Alunbrig is indicated for the treatment of patients with ALK+ metastatic NSCLC who have progressed on or are intolerant to crizotinib¹:

• Unprecedented Survival²*:
- 16.7 months median PFS^a (95% CI: 11.6-21.4, n=110)
- 34.1 months median OS (95% CI: 27.7 - NR, n=110)
• Robust Response^2*:
- 56% confirmed ORR^a (95% CI: 47-66, n=110)
• Durable CNS Efficacy^2*:
- 18.4 months median intracranial PFS^a,b (95% CI: 12.6-23.9, n =74)
- 67% confirmed intracranial ORR^a,c (95% CI: 41-87; n=18)

*at 180mg once daily regimen with a 7-day lead in at 90mg once daily
a=Independent Review Committee;
b= in patients with any brain metastases at baseline;
c=patients with measurable brain metastases at baseline

ALK+ = anaplastic lymphoma kinase positive; CI = confidence interval; CNS = central nervous system; NR = not reached; NSCLC = non small cell lung cancer; ORR = objective response rate; OS = overall survival; PFS = progression free survival

References:
1. Alunbrig HK prescribing information (HK-Nov18-US-Oct17)
2. Huber RM et al., J Thorac Oncol. 2020;15(3):404-415

Further information is available in MIMS section 9d and MIMS online.